New System Breaks Technology and Cost Barriers for High-Throughput Large-Genome Sequencing
By LabMedica International staff writers Posted on 28 Jan 2014 |

Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
A new DNA sequencing system utilizes advanced design features to generate massive throughput and enable the world's first USD 1000 human genome sequence.
This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.
Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.
Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.
Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).
“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.
Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”
“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”
Related Links:
Illumina
This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.
Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.
Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.
Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).
“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.
Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”
“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”
Related Links:
Illumina
Latest Technology News
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
- Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes
- Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
- New Method Advances AI Reliability with Applications in Medical Diagnostics
- Self-Powered Microneedle Patch Collects Biomarker Samples Without Drawing Blood
- Skin Patch Detects Biomarkers in Interstitial Fluid Without Blood Draws
- Handheld Saliva Test Accurately Detects Breast Cancer
- Cutting-Edge AI Algorithms Enable Early Detection of Prostate Cancer
- New Microfluidic System Enables Early Cancer Diagnosis Using Simple Blood Tests
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read moreMolecular Diagnostics
view channel
2-Hour Cancer Blood Test to Transform Tumor Detection
Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more
Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research
Alzheimer’s disease and other neurodegenerative disorders remain difficult to diagnose and monitor accurately due to limitations in existing biomarkers. Traditional tau and phosphorylated tau measurements... Read more
Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients
HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read moreHematology
view channel
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Novel Tool Uses Deep Learning for Precision Cancer Therapy
Nearly 50 new cancer therapies are approved each year, but selecting the right one for patients with highly individual tumor characteristics remains a major challenge. Physicians struggle to navigate the... Read more
Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read moreMicrobiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read moreIndustry
view channel
VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.... Read more